Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning

Sophie Gosselin(McGill University Health Centre), Lotte C. G. Hoegberg(Bispebjerg Hospital), Robert S. Hoffman(New York University), Andis Graudins(Monash Health), Christine M. Stork(SUNY Upstate Medical University), Simon H. L. Thomas(Newcastle University), Samuel J. Stellpflug(Regions Hospital), Bryan D. Hayes(University of Maryland, Baltimore), Michael Levine(University of Southern California), Martin Morris(McGill University), Andrea Nesbitt-Miller(McGill University), Alexis F. Turgeon(Université Laval), Benoît Bailey(Centre Hospitalier Universitaire Sainte-Justine), Diane P. Calello(Morristown Medical Center), Ryan Chuang(University of Calgary), Theodore C. Bania(St. Luke's-Roosevelt Hospital Center), Bruno Mégarbane(Inserm), Ashish Bhalla(Post Graduate Institute of Medical Education and Research), Valéry Lavergne(Université de Montréal)
Clinical Toxicology
September 8, 2016
Cited by 186Open Access
Full Text

Abstract

BACKGROUND: Although intravenous lipid emulsion (ILE) was first used to treat life-threatening local anesthetic (LA) toxicity, its use has expanded to include both non-local anesthetic (non-LA) poisoning and less severe manifestations of toxicity. A collaborative workgroup appraised the literature and provides evidence-based recommendations for the use of ILE in poisoning. METHODS: Following a systematic review of the literature, data were summarized in four publications: LA and non-LA poisoning efficacy, adverse effects, and analytical interferences. Twenty-two toxins or toxin categories and three clinical situations were selected for voting. Voting statements were proposed using a predetermined format. A two-round modified Delphi method was used to reach consensus on the voting statements. Disagreement was quantified using RAND/UCLA Appropriateness Method. RESULTS: 20% as it is the formulation the most often reported. There is no evidence to support a recommendation for the best formulation of ILE for non-LAs. The voting panel is neutral regarding ILE dosing and infusion duration due to insufficient data for non-LAs. All recommendations were based on very low quality of evidence. CONCLUSION: Clinical recommendations regarding the use of ILE in poisoning were only possible in a small number of scenarios and were based mainly on very low quality of evidence, balance of expected risks and benefits, adverse effects, laboratory interferences as well as related costs and resources. The workgroup emphasizes that dose-finding and controlled studies reflecting human poisoning scenarios are required to advance knowledge of limitations, indications, adverse effects, effectiveness, and best regimen for ILE treatment.


Related Papers

No related papers found

Powered by citation graph analysis